CRSP
CRISPR Therapeutics AG
$63.99
+$2.89(+4.73%)
57
Overall
60
Value
72
Tech
39
Quality
Market Cap
$5.84B
Volume
3.02M
52W Range
$30.04 - $78.48
Target Price
$82.42
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719.0K | $915.0M | $1.2M | $371.2M | $37.3M | ||
| Total Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719.0K | $915.0M | $436.0K | $371.2M | $37.3M | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $101.2M | $110.3M | $130.3M | -- | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $5.2M | $41.0M | $3.1M | $289.6M | $719.0K | $811.9M | $-109.8M | $371.2M | $37.3M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-73.3M | $-105.6M | $-162.1M | $242.8M | $355.2M | $541.4M | $563.3M | $593.7M | $503.9M | ||
| Research & Development | $42.2M | $69.8M | $113.8M | $179.4M | $266.9M | $340.6M | $461.6M | $387.3M | $320.7M | ||
| Research Expense | $42.2M | $69.8M | $113.8M | $179.4M | $266.9M | $340.6M | $461.6M | $387.3M | $320.7M | ||
| Selling, General & Administrative | $31.1M | $35.8M | $48.3M | $63.5M | $88.2M | $99.7M | $102.5M | $76.2M | $73.0M | ||
| General & Administrative Expenses | $31.1M | $35.8M | $48.3M | $63.5M | $88.2M | $99.7M | $102.5M | $76.2M | $73.0M | ||
| Salaries & Wages | $-10.8M | $-20.6M | $-39.3M | -- | -- | -- | $97.9M | $81.0M | $86.6M | ||
| Depreciation & Amortization | $-900.0K | $-3.0M | $-3.5M | $4.7M | $9.1M | $17.9M | $24.1M | $19.8M | $19.2M | ||
| Depreciation & Amortization | $-900.0K | $-3.0M | $-3.5M | $4.7M | $9.1M | $17.9M | $24.1M | $19.8M | $19.2M | ||
| Other Operating Expenses | $-73.3M | $-105.6M | $-162.1M | $-2.8M | $-7.0M | $-101.2M | $-10.4M | $-9.7M | $-5.8M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-68.1M | $-64.6M | $-158.9M | $46.7M | $-354.4M | $373.5M | $-673.2M | $-222.5M | $-466.6M | ||
| EBITDA | $-21.8M | $-63.6M | $-160.9M | $72.0M | $-345.3M | $391.5M | $-626.3M | $-130.9M | $-343.4M | ||
| NON-OPERATING ITEMS | |||||||||||
| Intinc | $-8.1M | -- | -- | -- | -- | -- | -- | $76.4M | $104.3M | ||
| Net Non-Operating Interest Income/Expense | $-8.1M | -- | -- | -- | -- | -- | -- | $76.4M | $104.3M | ||
| Other Income/Expense | $-53.5M | $2.0M | $5.5M | $-20.6M | $-6.4M | $-6.0M | $22.7M | $-71.8M | $-103.9M | ||
| Other Special Charges | $90.0M | $-197.0K | $-1.2M | $26.0M | $6.4M | $6.0M | $22.7M | $71.8M | $103.9M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-22.7M | $-66.6M | $-164.4M | $67.3M | $-354.4M | $373.5M | $-650.5M | $-150.7M | $-362.7M | ||
| Pre-Tax Income | $-22.7M | $-66.6M | $-164.4M | $67.3M | $-348.1M | $379.5M | $-650.5M | $-150.7M | $-362.7M | ||
| INCOME TAX | |||||||||||
| Tax Provision | $484.0K | $1.7M | $553.0K | $448.0K | $809.0K | $1.9M | $-325.0K | $2.9M | $3.6M | ||
| NET INCOME | |||||||||||
| Net Income | $-23.2M | $-68.4M | $-165.0M | $66.9M | $-348.9M | $377.7M | $-650.2M | $-153.6M | $-366.3M | ||
| Net Income (Continuing Operations) | $-23.2M | $-68.4M | $-165.0M | $66.9M | $-348.9M | $377.7M | $-650.2M | $-153.6M | $-366.3M | ||
| Net Income (Discontinued Operations) | $-23.2M | $-68.4M | $-165.0M | $66.9M | $-348.9M | $377.7M | $-650.2M | $-153.6M | $-366.3M | ||
| Net Income (Common Stockholders) | $-23.2M | $-68.4M | $-165.0M | $66.9M | $-348.9M | $377.7M | $-650.2M | $-153.6M | $-366.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-359.0M | ||
| TOTALS | |||||||||||
| Total Expenses | $-73.3M | $-105.6M | $-162.1M | $242.8M | $355.2M | $541.4M | $673.6M | $593.7M | $503.9M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $12.3M | $40.1M | $48.0M | $54.4M | $65.9M | $75.9M | $77.7M | $79.2M | $84.4M | ||
| Average Shares Outstanding (Diluted) | $35.0M | $41.6M | $48.0M | $56.9M | $65.9M | $80.4M | $77.7M | $79.2M | $84.4M | ||
| Shares Outstanding | $39.8M | $47.0M | $52.3M | $60.8M | $75.4M | $77.1M | $78.6M | $80.3M | $85.8M | ||
| Basic EPS | $0.43 | -- | $-3.44 | $1.23 | $-5.29 | $4.97 | $-8.36 | $-1.94 | $-4.34 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $1.23 | $-5.29 | $4.97 | $-8.36 | $-1.94 | $-4.34 | ||
| Diluted EPS | $-1.89 | $-1.71 | $-3.44 | $1.17 | $-5.29 | $4.7 | $-8.36 | $-1.94 | $-4.34 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $1.17 | $-5.29 | $4.7 | $-8.36 | $-1.94 | $-4.34 | ||
| OTHER METRICS | |||||||||||
| Earnings from equity interest | $-36.5M | $-1.8M | $-4.3M | $-5.5M | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-36.5M | $-1.8M | $-4.3M | $-5.5M | -- | -- | -- | -- | -- | ||
| Minority Interests | $25.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $31.1M | $35.8M | $48.3M | $63.5M | $88.2M | $99.7M | $102.5M | $76.2M | $73.0M | ||
| Rent And Landing Fees | $31.1M | $35.8M | $48.3M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRSP | $63.99 | +4.7% | 3.02M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |